Wockhardt said that it will market a patented drug used in treatment of osteoporosis in the country.
Switzerland-based DSM Nutritional Products, the patent holder of Bonistein, has licensed the drug to Wockhardt, the Indian biotech company said in a statement.
Habil Khorakiwala, chairman, Wockhardt, said: "This will strengthen our orthopaedic portfolio."
In India, the market for osteoporosis formulations market is over Rs 250 crore, as per data from ORG IMS. This market is growing at 19 per cent.
The biotech major plans to launch the medicine in mid-2009.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app